MXPA02008213A - Compuestos piperazina sustituidos. - Google Patents

Compuestos piperazina sustituidos.

Info

Publication number
MXPA02008213A
MXPA02008213A MXPA02008213A MXPA02008213A MXPA02008213A MX PA02008213 A MXPA02008213 A MX PA02008213A MX PA02008213 A MXPA02008213 A MX PA02008213A MX PA02008213 A MXPA02008213 A MX PA02008213A MX PA02008213 A MXPA02008213 A MX PA02008213A
Authority
MX
Mexico
Prior art keywords
angina
skeletal muscles
compounds
protect skeletal
substituted piperazine
Prior art date
Application number
MXPA02008213A
Other languages
English (en)
Inventor
Venkata P Palle
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of MXPA02008213A publication Critical patent/MXPA02008213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se describen compuestos novedosos de la formula general: (ver formula) y sales acidas de adicion farmaceuticamente aceptable de los mismos, en donde los compuestos son utiles en la terapia para proteger los musculos esqueleticos en contra del dano resultante del trauma o para proteger los musculos esqueleticos subsecuentes de las enfermedades sistemicas o musculares tales como claudicacion intermitente, para tratar las condiciones de shock, para preservar el tejido donado y los organos usados en transplantes en el tratamiento de las enfermedades cardiovasculares que incluyen arritmias ventriculares y atriales, la angina de Prinzmetal (variante), la angina estable y la angina inducida por ejercicio, la enfermedad cardiaca congestiva y el infarto al miocardio.
MXPA02008213A 2000-02-22 2001-02-22 Compuestos piperazina sustituidos. MXPA02008213A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18418200P 2000-02-22 2000-02-22
US18430600P 2000-02-22 2000-02-22
US18445700P 2000-02-22 2000-02-22
US20639600P 2000-05-23 2000-05-23
US20926200P 2000-06-05 2000-06-05
PCT/US2001/005606 WO2001062744A2 (en) 2000-02-22 2001-02-22 Substituted piperazine compounds

Publications (1)

Publication Number Publication Date
MXPA02008213A true MXPA02008213A (es) 2004-04-05

Family

ID=27539118

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008213A MXPA02008213A (es) 2000-02-22 2001-02-22 Compuestos piperazina sustituidos.

Country Status (14)

Country Link
EP (1) EP1259493A2 (es)
JP (2) JP3980885B2 (es)
KR (1) KR100595942B1 (es)
CN (1) CN1404471A (es)
AR (1) AR029229A1 (es)
AU (2) AU3862301A (es)
BR (1) BR0108592A (es)
CA (2) CA2657986A1 (es)
IL (1) IL151178A0 (es)
MX (1) MXPA02008213A (es)
NO (1) NO324837B1 (es)
NZ (1) NZ520782A (es)
TW (1) TWI236471B (es)
WO (1) WO2001062744A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0108452A (pt) * 2000-02-18 2003-04-01 Cv Therapeutics Inc Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
US7001909B2 (en) 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
PT1406898E (pt) * 2001-07-19 2005-08-31 Cv Therapeutics Inc Compostos de piperazina substituida e sua utilizacao como inibidores de oxidacao de acidos gordos
EP1806346B1 (en) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
EP1567525B1 (en) * 2002-12-05 2007-06-27 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
WO2004063180A1 (en) * 2003-01-03 2004-07-29 Cv Therapeutics, Inc. Substituted heterocyclic compounds
WO2005000826A1 (en) * 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
AU2004303882A1 (en) 2003-12-18 2005-07-07 Gilead Palo Alto, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
JP2008512465A (ja) * 2004-09-08 2008-04-24 シーブイ・セラピューティクス・インコーポレイテッド 脂肪酸酸化阻害剤としての置換ピペラジン化合物およびその使用
CN102875490A (zh) * 2012-10-19 2013-01-16 四川大学 一种用于制备雷诺嗪的合成方法
CN107043361B (zh) * 2017-05-25 2019-07-02 合肥医工医药股份有限公司 治疗心绞痛的化合物、制备方法及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
JPS584774A (ja) * 1981-06-23 1983-01-11 ジヤンセン・フア−マシユ−チカ・ナ−ムロ−ゼ・フエンノ−トシヤツプ Ｎ−アリ−ル−ピペラジンアルカンアミド類
US4558129A (en) * 1983-05-18 1985-12-10 Syntex (U.S.A.) Inc. Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
FR2552083B1 (fr) * 1983-09-15 1986-05-09 Cerm Cent Europ Rech Mauvernay Derives de (alkynyloxy-3 hydroxy-2-propyl)-4 piperazinyl-1 n-phenyl acetamide, leur preparation et leur application en therapeutique
EP0714660B1 (en) * 1989-06-23 2002-09-04 Syntex (U.S.A.) LLC Ranolazine and related piperazines for protecting skeletal muscles
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
HU209723B (en) * 1990-10-31 1994-10-28 Richter Gedeon Vegyeszet Process for producing of piperazine derivatives

Also Published As

Publication number Publication date
JP3980885B2 (ja) 2007-09-26
AU3862301A (en) 2001-09-03
KR100595942B1 (ko) 2006-07-03
WO2001062744A3 (en) 2002-02-07
AU2001238623B2 (en) 2004-09-23
NO20023954L (no) 2002-09-30
NO20023954D0 (no) 2002-08-20
WO2001062744A2 (en) 2001-08-30
BR0108592A (pt) 2004-06-29
AR029229A1 (es) 2003-06-18
CA2400176C (en) 2009-04-28
NZ520782A (en) 2004-03-26
KR20020079893A (ko) 2002-10-19
TWI236471B (en) 2005-07-21
JP2003531116A (ja) 2003-10-21
IL151178A0 (en) 2003-04-10
CN1404471A (zh) 2003-03-19
CA2657986A1 (en) 2001-08-30
NO324837B1 (no) 2007-12-17
CA2400176A1 (en) 2001-08-30
EP1259493A2 (en) 2002-11-27
JP2007211009A (ja) 2007-08-23

Similar Documents

Publication Publication Date Title
TR200201059T2 (tr) Kardiyak arritmialarının tedavisinde kullanışlı yeni oksabispidin bileşimleri
RS82003A (en) Anthranilic acid amides, method for the production thereof, their use as antiarhythmia agents, and pharmaceutical preparations thereof
TWI256950B (en) Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
WO2003059266A3 (en) Post-conditioning for the reduction of ischemic-reperfusion injury in the heart and other organs
MXPA02008213A (es) Compuestos piperazina sustituidos.
MY138341A (en) Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use
WO2003050261A3 (en) (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
YU24402A (sh) 2'-supstituisani 1,1'-bifenil-2-karbonamidi, postupak za njihovu proizvodnju, njihova primena kao leka kao i farmaceutski preparati koji sadrže ta jedinjenja
HK1064374A1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors.
WO2001062711A3 (en) Substituted alkylene diamine compounds
MY136788A (en) 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment or cardiac arrhythmias
NO20070148L (no) Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen
NO20070147L (no) Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen
HK1085467A1 (en) Substituted heterocyclic compounds
SE0003795D0 (sv) Pharmaceutically useful compounds
NO20000016L (no) Sykliske azapeptider med angiogen virkning
MXPA05011428A (es) Metodo de tratamiento de fibrilacion atrial o trepidacion auricular.
RS20050690A (sr) 2-(butil-1-sulfonilamino)-n-/1(r)-(6- metoksi-piridin-3-il)- propil/- benzamid, njegova primena u svojstvu leka kao i farmaceutski preparati koji sadrže ova jedinjenja
ATE365737T1 (de) Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren
WO2004067506A3 (en) Substituted heterocyclic compounds
RU2002113667A (ru) Применение 2-амино-3,4-дигидрохиназолинов для получения лекарственного средства для лечения и профилактики заболеваний, вызываемых ишемическими состояниями
AR024577A1 (es) Nuevos compuestos de bispidina utiles en el tratamiento de arritmias cardiacas
HRP20010845A9 (en) Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives
AR024393A1 (es) Nuevos compuestos de bispidina para usar en el tratamiento de las arritmias cardiacas.

Legal Events

Date Code Title Description
FG Grant or registration